1. Introduction {#sec1}
===============

Since the results of the Human Genome Project were made known in June 2000, the promise of personalized medicine has been actively pursued; however, this remains in its infancy and there is consensus that further research is needed before personalized medicine becomes an actuality. Although oriental medicine cannot be regarded as personalized medicine, it can be regarded as a group-customized medicine, because it does not treat a condition in the same way across the board, but treatments differ according to the constitutional group to which the patient belongs \[[@B1]\]. Oriental constitutional medicine provides a way to balance human body and mind according to the constitution, not only for the treatment of diseases but also for healthy living \[[@B2]\].

Constitutional medicine in Korea is called Sasang. Sasang constitutional medicine was initiated by Jema Lee (1837--1900) and is the most representative traditional medicine of Korea. It uses an approach of considering how diseases progress differently among different constitutional groups of people and administering treatments based on the recognition of distinct patterns present in each constitutional type \[[@B3]\]. The constitution is classified into four types according to individual\'s physical and psychological characteristics \[[@B4]\]: Taeyangin (TY), Soyangin (SY), Taeeumin (TE), and Soeumin (SE) \[[@B2]\]. Traditional Korean medicine doctors claim that determination of the constitutional types could be valuable for the prevention and treatment of diseases, because disease susceptibilities and drug responses vary depending on the individual\'s constitution \[[@B5]\], although scientific evidence is still required to verify this claim.

Although the scientific basis of constitutional medicine is still in question, constitution-based oriental medicine is recognized as a medical practice in Korea. However, the Sasang constitution has the disadvantage that it is difficult to diagnose objectively, as the diagnosis of the constitution is made according to the subjective view of the oriental medicine doctor. If a scientific validation method could be developed which allows easy determination of the constitution, it will be highly useful in oriental medicine. Numerous attempts have been made to classify the constitution scientifically; the Questionnaire for Sasang Constitution Classification II (QSCC II) has recently been developed and has been used as a validated, objective assessment \[[@B6]\], although it is continuously being supplemented with additional surveys to improve the accuracy of determination \[[@B7]\]. Questionnaires about the face, body, shape, and personal characteristics have been used in trials of Sasang constitutional diagnosis \[[@B8]\]. Moreover, discrimination of the Sasang constitution, depending on the characteristics of the skin, fingerprints, and voice, has been reported \[[@B9]--[@B11]\].

In metabolomics, the causes of life phenomena are systematically identified by analyzing the composition and concentration of metabolic groups that change under various genetic, physiological, or environmental conditions \[[@B12]\]. The emerging field of "metabolomics," in which a large number of small molecules from body fluids or tissues are detected quantitatively in a single step, holds immense potential for early diagnosis, identification of novel drug targets, customized drug treatment, therapy monitoring, and advances in the understanding of the pathogenesis of many diseases \[[@B13]\]. To date, no study has reported the relationship between Sasang constitution and metabolites.

Our study investigated whether blood metabolites differ significantly depending on the Sasang constitution as classified by QSCCII diagnosis. Polar metabolites and lipids were identified using liquid chromatography-mass spectrometry- (LC-MS-) based metabolomics and lipidomics. The analysis was performed on only three of the Sasang constitutions, as the TY constitution is very rare.

2. Materials And Methods {#sec2}
========================

2.1. Subjects and Study Design {#sec2.1}
------------------------------

This human study was approved (KMISC-FD-22) by Daegu Oriental Hospital of Daegu Haany University (Daegu, South Korea). Healthy Korean males between 21 and 29 years of age were recruited. Each participant was grouped according to Sasang constitutional types (SCT), using the integrated diagnosis model combining four individual models based on Questionnaire for Sasang Constitutional Classification II (QSCC II), face, body shape, and voice, by oriental medicine doctors (Daegu Haany University Medical Center). Participants with a body mass index (BMI) \< 18.5 kg/m^2^ or \> 30 kg/m^2^ \[[@B14]\], hypertension, and ALT and AST greater than twice the normal upper limit or who were participating in any other study or had donated blood during the last 1 month before the start of this study or had preexisting chronic diseases or were taking drugs were excluded. Fifteen TE, 15 SY, and 18 SE individuals were identified. The TY type is extremely rare in the population \[[@B15]\], and no such subjects were classified in our study. The subjects had fasted 10--17 h prior to collection of blood samples in an EDTA plasma tube. Blood samples were centrifuged at 1550 ×*g* for 10 min at 4°C to collect the plasma. General characteristics of the participants, such as BMI, waist-to-hip ratio (WHR), visceral fat area (VFA), blood pressure, and plasma lipid profiles, were determined.

2.2. Metabolomics Analysis {#sec2.2}
--------------------------

Plasma protein was precipitated by addition of cold acetonitrile. After shaking for 30 min at 4°C, the samples were centrifuged at 9,000 × g for 10 min at 4°C and the supernatant was dissolved in 20% aqueous methanol containing caffeine \[[@B16]\]. The analyses were performed using an ACQUITY Ultra-Performance Liquid Chromatography (UPLC) system (Waters, Milford, MA, USA) coupled to an ultra-performance liquid chromatography-quadrupole time of flight mass spectrometry (UPLC-ESI/Q-TOF) system (Waters Corp., Manchester, UK) with ACQUITY UPLC BEH C18 (2.1 × 100 mm, 1.7 *μ*m) column. The column temperature was conditioned at 30°C. The flow rate was set at 0.30 *μ*l/min. The mobile phase was composed of (A) 0.1% formic acid aqueous solution and (B) 0.1% formic acid in acetonitrile, at an injection volume of 5 *μ*l. The conditions were as follows: initial condition of 98% A, 0--13 min with 98--5% A, and 13--14 min with 5% A and returning to 98% A for a 2 min reequilibration step. The mass spectrometer was a Waters SYNAPT G2-Si mass spectrometer with an electrospray ionization (ESI) mode. The ESI source was set in positive and negative ESI mode with a scan range of m/z 50--1,000. Argon was used as collision gas, and nitrogen was used as desolvation gas. The voltage of capillary, cone, and collision energy was set at 3.0 kV, 40 V, and 25 V, respectively. The gas flow for desolvation and cone was 800 and 50 L/h. The source temperature and desolvation gas temperature were 110 and 350°C, respectively.

2.3. Lipidomics Analysis {#sec2.3}
------------------------

The sample extraction is briefly described as follows \[[@B17], [@B18]\]. Serum samples (50 *µ*l) were extracted with a mixture of chloroform and methanol (1:2; 200 *µ*l). This solution was then vortexed for 30 min at room temperature and immediately vortexed. The sample was centrifuged at 13,000 rpm at 4°C. The supernatant was completely evaporated under a stream of nitrogen. The lipid extract was diluted with an isopropanol : acetonitrile : water (2:1:1, v/v/v) solution. Lipid extracts were analyzed on a SYNAPT G2-Si mass spectrometer (Waters, Manchester, UK) coupled to an ACQUITY UPLC system (Waters, Milford, MA, USA) with an ACQUITY UPLC CSH C18 (2.1 × 100 mm, 1.7 *μ*m) column. The column temperature was set at 55°C. Mobile phase A was 10 mM ammonium acetate and 0.1% formic acid in an acetonitrile : water mixture (60:40, v/v); mobile phase B was 10 mM ammonium acetate and 0.1% formic acid in an isopropanol : acetonitrile mixture (90:10, v/v). The gradient profile was 60-43% B over 2 min, 50% B at 2.1 min, 54% B at 12 min, and 99% B at 18 min, followed by equilibration at 40% B for 2 min at a flow rate of 0.4 *μ*l/min. The Q-TOF-MS was operated in positive and negative electrospray ionization mode within a mass range of 100--1,000*m/z*. The source temperature was set at 120°C, voltage of the sampling cone is 30 V, and the desolvation gas (800 L/h) is at 250°C. The collision energy was ramped from 20 to 35 V and the capillary voltages were set at 2.0 kV (for positive) and 1.0 kV (for negative). All spectrum data were collected in continuum format using the MS^E^ acquisition mode. Mass accuracy was calibrated using sodium format, and leucine enkephalin was used as lock mass.

2.4. Data Processing And Statistical Analysis {#sec2.4}
---------------------------------------------

The raw data were processed using Progenesis QI data analysis software (Nonlinear Dynamics, Newcastle, UK) for chromatographic alignment, normalization, peak picking, and compound identification. The resulting data sets were imported into SIMCA-P version 12.0.1 (Umetrics, Umeå, Sweden) for multivariate analysis and were mean-centered scaled. Assignment of metabolites contributing to the observed variance was performed using ChemSpider (<http://www.chemspider.com>), Human Metabolome Database (<http://www.hmdb.ca>), and LIPID MAPS (<http://www.lipidmaps.org>). Metabolic pathway analysis was performed using MetaboAnalyst 3.0 (<http://www.metaboanalyst.ca>), which is based on database sources such as KEGG and HMDB, to identify the metabolic pathways that are affected and to facilitate biological interpretation. One-way analysis for variance (ANOVA) with Tukey\'s post hoc tests was carried out for the comparison between three groups. Potential biomarkers were selected using VIP \> 1 and*P*\< 0.05.

3. Results {#sec3}
==========

3.1. Subjects\' Characteristics {#sec3.1}
-------------------------------

[Table 1](#tab1){ref-type="table"} shows the general characteristics of participants. There were significant differences between the three groups in terms of BMI, body fat percentage (BFP), WHR, VFA, and systolic blood pressure (SBP). Although there was no significant difference between the SY and TE groups, both groups were significantly different from the SE group. SE persons have a more skinny body phenotype than SY and TE persons. This result is consistent with the results of previous studies showing a relatively low BMI for SE people \[[@B19]\]. In addition, total cholesterol (TC) was higher in the TE group than in the SY group; however, there was no significant difference when compared to the SE group. SBP levels were higher in the TE and SY groups than in the SE group. It is known that there may be constitutions among the Sasang constitutions that are likely to become obese and that there are differences in constitutional characteristics according to lifestyle.

3.2. Metabolic Profiles of Plasma Samples {#sec3.2}
-----------------------------------------

The metabolomic profiles of plasma samples from the three groups (15 TE, 15 SY, and 18 SE) were characterized and compared. A total of 3,000 molecular features in positive and negative modes were obtained and subjected to statistical analysis using Progenesis Q1 and SIMCA-P version 12.0.1 software, including partial least-squares discriminant analysis (PLS-DA). As shown in the PLS-DA score plots, the TE group was significantly separated from the other two groups (Figures [1(a)](#fig1){ref-type="fig"} and [1(c)](#fig1){ref-type="fig"}). On the other hand, there was no significant difference between the SY and SE groups. The PLS-DA score plots between the Sasang constitutions showed a similar pattern in both negative and positive ion modes. The validation plots from the permutation tests strongly supported the validity of the PLS-DA scores (Figures [1(b)](#fig1){ref-type="fig"} and [1(d)](#fig1){ref-type="fig"}). Validity was supported by the finding that all permuted R^2^ and Q^2^ values on the left were lower than the original point on the right and that the Q^2^ regression line (in blue in the plots in [Figure 1](#fig1){ref-type="fig"}) had a negative intercept.

A total of 33 metabolites (VIP \> 1,*P* \< 0.05) were identified as potential biomarkers for diagnosis of Sasang constitution types ([Table 2](#tab2){ref-type="table"}). Among the 33 metabolites, the intensity of 27 metabolites showed the same tendency in order of TE, SE, and SY groups. In a comparison of the TE and SY groups, a total of 23 metabolites, such as 3-hydroxybutyric acid, leucine, caffeic acid, melatonin, and phenyllactic acid, were significantly higher in the TE than in the SY types. In addition, the levels of 4-hydroxybenzaldehyde, glutamic acid, leucine, indole-3-lactic acid, acetylcarnitine, melatonin, and stearoylcarnitine were significantly different between the TE and SE groups. Eight significant metabolites were identified in the comparison of the SY and SE groups. In particular, glutamic acid may be a potential biomarker candidate for the diagnosis of Sasang constitution type. The relative intensity of each metabolite in the sample from each group was shown in heat map ([Figure 3(a)](#fig3){ref-type="fig"}) MetaboAnalyst indicates that 11 pathways, such as phenylalanine metabolism; aminoacyl-tRNA biosynthesis; tyrosine and tryptophan biosynthesis; D-glutamine and D-glutamate metabolism; valine, leucine, and isoleucine biosynthesis; and nitrogen metabolism, were regarded as the targeted metabolic pathways ([Figure 3(b)](#fig3){ref-type="fig"}). This result suggests that the difference in Sasang constitutions mainly involves differences in amino-acid-related metabolism.

3.3. Lipidomic Profiles of Plasma Samples {#sec3.3}
-----------------------------------------

SE persons are characterized by having a slender body shape, unlike TE and SY persons \[[@B5]\]. Lipid profiling of individuals with these different constitutions was expected to show a clear trend between the SE and the other two constitutions. The PLS-DA score plots showed a significant separation between the TE and the other two constitutions in both positive and negative modes (Figures [2(a)](#fig2){ref-type="fig"} and [2(c)](#fig2){ref-type="fig"}). The validation tests supported the validity of the PLS-DA models (Figures [2(b)](#fig2){ref-type="fig"} and [2(d)](#fig2){ref-type="fig"}). Although there was no significant difference in the lipid profiles of the SE and SY groups, the significance in the negative and positive modes was 0.077 and 0.06, respectively. Moreover, we identified 36 lipids ([Table 3](#tab3){ref-type="table"}). Among the 36 metabolites, 16 metabolites, such as FA (20:4), FA (22:5), FA (22:6), LPC (16:1), LPE (16:0), LPI (18:0), PC (32:1), PC (33:1), PC (34:1), 1-deoxysphinganine, sphinganine (d18:1), and sphinganine (d20:1), were significantly grouped among the three groups. In the comparison of the SY and SE groups, 20 fatty acids showed significant differences, which was more than the eight metabolites showing differences in the metabolomics profiles. Our results showed that the lipidomic analysis showed that the SY group was characterized by different lipid profiles as compared with SE group ([Figure 3(a)](#fig3){ref-type="fig"}). Interestingly, MetaboAnalyst analysis showed that there were five canonical pathways that may be related to Sasang constitutions ([Figure 3(c)](#fig3){ref-type="fig"}); the top two pathways were glycerophospholipid and arachidonic acid metabolism. In the SY group, these metabolic pathways were more activated than in the SE and TE groups.

4. Discussion {#sec4}
=============

This study investigated whether metabolomics and lipidomics analyses of human plasma could classify the Sasang constitution types. Sasang constitutional medicine prescribes medicinal herbs according to the individual type, based on the biopsychosocial perspectives \[[@B5]\]. In terms of personalized medicine, which is a current focus point, it is surprising that such an analysis has not yet been reported. In an effort to develop a method for classifying Sasang constitution type, QSCC II method was developed \[[@B8]\], which could assist practitioners in diagnosing the Sasang constitution type but was limited in terms of scientific evidence \[[@B6], [@B20]\]. The accurate classification of Sasang constitution type has been a major concern in both conventional and complementary medicine and could play an important role in oriental medical prescriptions and treatment for certain diseases, such as stroke, diabetes, and metabolic syndrome \[[@B15], [@B21]--[@B23]\].

In this study, we first investigated the use of metabolomics for classifying the Sasang constitution types, as metabolic analysis has the advantage of allowing the prediction or diagnosis of human diseases, such as cancer, diabetes, and chronic liver disease \[[@B13], [@B24]--[@B26]\]. Our results showed the possibility of classifying Sasang constitution types by analyzing both metabolomics and lipidomics. The TE group was significantly separated from the SE and SY groups by metabolomics analysis, although it was not possible to distinguish between SY and SE groups. We also applied global lipid profiling to plasma to further clarify the metabolic differences between each constitution type. The results were similar to the amino-acid-related metabolites; interestingly, the lipid profiles showed the possibility to distinguish the difference between the SE and SY groups (*p* = 0.06); thus, with a larger scale study, it may be possible to distinguish these two constitutions.

It has been reported that TE persons have a high prevalence rate of obesity due to hypoactivity of their energy metabolism \[[@B3], [@B22], [@B27]\]. The BMI of TE group was similar to that of the SY group, but the amino acids and lipid metabolites showed a significant difference between the TE and SY groups. Although the total cholesterol levels of the TE group were significantly higher than that of the SY group, they were within the normal range. The branched-chain amino acids, that is, lysine, tryptophan, cysteine, and glutamate, have been found to be present at high levels in obese individuals \[[@B28]\]. In our study, valine, glutamate, leucine, and lysine were more prevalent in the TE group than in the SE and SY groups, suggesting that metabolomics analysis can provide a scientific basis for explaining the proclivity of TE people to progress to obesity. Lysine and glutamic acid levels were also higher in the TE group. In particular, glutamic acid levels were significantly different among the three groups. Among the four Sasang types, TE persons had significantly higher total cholesterol and triglyceride (TG) values in the blood than other constitutions \[[@B3]\]. TE persons are more likely to be obese than other constitutions; however, our results showed that the BMI in the TE group was significantly different from that of the SE group but was not different from that of the SY group.

The concentration of lipid metabolites of the SY group was greater than that of the TE group. Levels of glycerophospholipids, lysolipids, glycerolipids, and shphingolipids differed significantly between each Sasang type, and levels were particularly higher in the SY group than in the TE groups. Low lipid concentrations may represent hypoactivity of lipid metabolism, and it is presumed that TE persons are more likely to be obese than an SY person with the same BMI; BMI is used to define obesity. Among the identified biomarkers, we found some interesting and compelling results: the level of 1-deoxysphinganine in the SY group was much higher than that in the other two constitution types. These levels are also elevated in diabetic patients and have been suggested to represent an early biomarker \[[@B29]--[@B31]\]. TE individuals have higher prevalence of diabetes than the other two types \[[@B32]\]. Since 1-deoxysphinganine is a toxic lipid for insulin-producing pancreatic *β* cells \[[@B29]\], people with lower concentrations of the 1-deoxysphinganine can be more sensitive to this substance. In some circumstances, an increase in this substance in TE people may increase the incidence of diabetes mellitus rather than its incidence in SY people.

This study had some limitations. First, it involved a small sample size, which was inadequate to confirm the accuracy of the classification of the Sasang constitution type. Therefore, current evidence of metabolomics/lipidomics-based Sasang constitution medicine is insufficient to recommend classification according to constitution type. Second, the correlation between constitution and metabolite profiles in this study was based on healthy individuals in their twenties. So, it is not clear at this stage whether the metabolite profiles will hold across different age groups and health/disease conditions. In addition, since this study focused on male participants, further research is needed to identify gender differences in metabolites. One more limitation of this study is that it did not consider the environmental factors such as eating habit and lifestyle which might affect the results.

Collectively, the profiles of blood metabolites in TE and SY constitution types differ. Even when such individuals have the same BMI, it may thus be possible to distinguish between the two constitution types through metabolite analysis. Although this was a pilot study, the data revealed the possibility of diagnosis of the Sasang constitution type based on metabolomics and lipidomics analysis. Further clinical trials are required to verify these findings.

The authors thank Professor MR Kim and AR Choi at Daegu Haany University\'s Daegu Oriental Hospital for supporting this investigation. This research was supported by Main Research Program of the Korea Food Research Institute (KFRI) funded by the Ministry of Science, ICT, and Future Planning.

BFP:

:   Body fat percentage

BMI:

:   Body mass index

PLS-DA:

:   Partial least-squares discriminant analysis

QSCC II:

:   Questionnaire for Sasang Constitution Classification II

SBP:

:   Systolic blood pressure

SE:

:   Soeumin

SY:

:   Soyangin

TC:

:   Total cholesterol

TE:

:   Taeeumin

TG:

:   Total triglyceride

VFA:

:   Visceral fat area

WHR:

:   Waist-to-hip ratio.

Conflicts of Interest
=====================

The authors declare that they have no conflicts of interest related to this study.

Authors\' Contributions
=======================

Chang Hwa Jung wrote the manuscript and was responsible for study conception and design. Min Jung Kim and Da-Hye Lee performed the LC-MS analysis and interpretation of data. Jiyun Ahn, Eunju Do, and Tae-Youl Ha analyzed the data. All authors approved the final version of the manuscript.

![Partial least-squares discriminant analysis (PLS-DA) score and permutation results from plasma metabolites of participants classified according to Sasang constitution types based on metabolomics analysis. (a) PLS-DA score plot in ESI- mode. (b) Validation plot in ESI- mode. (c) PLS-DA score plot in ESI+ mode. (d) Validation plot in ESI+ mode. SY: Soyangin; TE: Taeeumin; SE: Soeumin.](ECAM2018-9214960.001){#fig1}

![Partial least-squares discriminant analysis (PLS-DA) score and permutation results from plasma metabolites of participants classified according to Sasang constitution types using lipidomics analysis. (a) PLS-DA score plot in ESI- mode. (b) Validation plot in ESI- mode. (c) PLS-DA score plot in ESI+ mode. (d) Validation plot in ESI+ mode. SY: Soyangin; TE: Taeeumin; SE: Soeumin.](ECAM2018-9214960.002){#fig2}

![Heat map and metabolic pathway of metabolites identified by metabolomics and lipidomics analysis. (a) Heat map of identified metabolites. (b) Amino acid metabolism. (c) Lipid metabolism. SY: Soyangin; TE: Taeeumin; SE: Soeumin.](ECAM2018-9214960.003){#fig3}

###### 

General characteristics of participants.

  Variable              SY                  TE                  SE                   *P* value
  --------------------- ------------------- ------------------- -------------------- ------------------
  No. of participants   15                  15                  18                    
  Age (year)            24.07 ± 2.71        24.33 ± 2.02        23.67 ± 1.68         0.670
  BMI (kg/m^2^)         25.09 ±2.21^b^      25.57 ± 1.90^b^     21.36 ± 1.75^a^      \<0.0001^*∗∗∗∗*^
  BFP (%)               22.65 ± 4.34^b^     24.02 ± 4.06^b^     19.08 ± 4.79^a^      0.007^*∗∗*^
  WHR                   0.87 ± 0.03^b^      0.86 ± 0.04^b^      0.83 ± 0.03^a^       0.003^*∗∗*^
  VFA                   81.91 ± 28.34^b^    86.55 ± 19.62^b^    60.54 ± 25.64^a^     0.009^*∗*^
  Glucose (mg/dL)       92.20 ± 7.59        90.20 ± 4.04        91.61 ± 9.10         0.747
  TC (mg/dL)            161.20 ± 32.74^a^   186.60 ± 26.28^b^   168.67 ± 27.47^ab^   0.060
  TG (mg/dL)            126.87 ± 138.15     111.33 ± 65.40      74.22 ± 37.86        0.220
  SGOT                  22.73 ± 6.72^ab^    26.60 ± 11.63^b^    19.50 ± 4.42^a^      0.048^*∗*^
  SGPT                  33.87 ± 11.69       29.80 ± 13.21       24.39 ± 9.57         0.069
  *γ*-GPT               32.00 ± 11.59       28.40 ± 13.28       26.17 ± 10.10        0.363
  Protein (g/dL)        7.51 ± 0.26         7.57 ± 0.27         7.36 ± 0.30          0.090
  Albumin (g/dL)        4.67 ± 0.23         4.77 ± 0.24         4.76 ± 0.29          0.532
  SBP (mmHg)            127.40 ± 9.93^b^    126.27 ± 11.51^b^   117.56 ± 10.18^a^    0.018^*∗*^
  DBP (mmHg)            81.40 ± 8.77        81.47 ± 8.59        77.94 ± 7.77         0.382
  WBC (×10^3^/*μ*L)     6.03 ± 1.46         5.82 ± 1.32         5.94 ± 1.55          0.922
  RBC (×10^6^/*μ*L)     4.94 ± 0.43         5.11 ± 0.35         4.82 ± 0.40          0.121
  PLT (×10^3^/*μ*L)     261.87 ± 54.80      243.73 ± 43.89      235.17 ± 42.61       0.271

SY: Soyangin; TE: Taeeumin; SE: Soeumin; BMI: body mass index; BFP: body-fat percentage; WHR: waist-to-hip ratio; VFA: visceral fat area; TC: total cholesterol; TG: triglycerides; SGOT: serum glutamic oxaloacetic transaminase; SGPT: serum glutamic-pyruvic transaminase; *γ*-GPT: gamma-glutamyl transferase; SBP: systolic blood pressure; DBP: diastolic blood pressure; WBC: white blood cell; RBC: red blood cell; PLT: platelet cell. Differences among groups were analyzed using Duncan\'s multiple range test (*p* \< 0.05) and are indicated by different lowercase letters (a, b, and ab). Letter "a" is significant to "b," but "ab" is not significant. *∗*, *∗∗*, and *∗∗∗∗* denote one-way ANOVA (parametric test).

###### 

List of potential plasma biomarkers in three Sasang constitutions.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Tentative metabolites         m/z        Mass error\   Adduct       Fold change   *p* value     Pathway              
                                                 (mDa)                                                                       
  ----- ----------------------------- ---------- ------------- ------------ ------------- ------------- ------------ ------- ------------------------------------------------------
  1     Lactic acid                   89.0235                  M-H          1.49^*∗*^     1.19          0.80         0.090   Propanoate metabolism

  2     3-Hydroxybutyric acid         103.0388   -0.69         M-H          0.89          0.61^*∗*^     0.68         0.020   Synthesis and degradation of ketone bodies

  3     Valine                        118.0737   -13.13        M+H          1.01          0.85          0.85         0.076   Aminoacyl-tRNA biosynthesis\
                                                                                                                             Valine, leucine, and isoleucine biosynthesis

  4     4-Hydroxybenzaldehyde         121.0285   -0.53         M-H          0.92          0.81          0.75^*∗∗*^   0.041   Phenylalanine metabolism

  5     Benzoic acid                  123.0437   -0.94         M+H          1.15          1.17^*∗*^     1.02         0.115   Phenylalanine metabolism

  6     Pyrrolidonecarboxylic acid    128.0341   -0.73         M-H          0.98          0.78          0.77         0.068   D-glutamine and D-glutamate metabolism

  7     Glutamic acid                 130.0376   -12.79        M+H-H~2~O    0.89^*∗*^     0.79^*∗∗∗*^   0.89^*∗*^    0.000   Aminoacyl-tRNA biosynthesis\
                                                                                                                             D-Glutamine and D-glutamate metabolism

  8     Ornithine                     131.0811   -0.96         M-H          0.88          0.86^*∗*^     0.98         0.071   Glutathione metabolism

  9     Leucine                       132.0883   -14.17        M+H          0.88          0.45^*∗∗*^    0.40^*∗∗*^   0.002   Aminoacyl-tRNA biosynthesis\
                                                                                                                             Valine, leucine, and isoleucine biosynthesis

  10    Glutaric acid                 133.0562   6.11          M+H          0.92          0.84^*∗*^     0.92         0.045   Lysine degradation\
                                                                                                                             Fatty acid metabolism

  11    Adenine                       136.0622   -0.12         M+H          0.93          0.89^*∗*^     0.96         0.094   Purine metabolism

  12    Phenylacetamide               136.0632   -7.00         M+H          0.85          0.83^*∗*^     0.98         0.084   Phenylalanine metabolism

  13    Lysine                        145.0953   -2.37         M-H          1.18          1.10          0.93         0.105   Aminoacyl-tRNA biosynthesis

  14    Phenyllactic acid             147.0440   -0.63         M-H~2~O-H    0.88^*∗*^     0.89^*∗*^     0.99         0.038   Phenylalanine and tyrosine metabolism

  15    Methionine                    148.0421   -1.10         M-H          0.91          0.83^*∗*^     0.92         0.265   Aminoacyl-tRNA biosynthesis

  16    Caffeic acid                  163.0296   -9.86         M+H-H~2~O    0.38^*∗∗∗*^   0.40^*∗∗∗*^   0.94         0.000   Phenylpropanoid biosynthesis

  17    Hydroxyphenyllactic acid      163.0390   -0.51         M-H~2~O-H    0.95          0.80^*∗*^     0.84         0.157   Ubiquinone and other terpenoid-quinone biosynthesis

  18    Phenylalanine                 164.0701   -1.08         M-H          0.87^*∗*^     0.88^*∗*^     0.99         0.019   Phenylalanine metabolism\
                                                                                                                             Aminoacyl-tRNA biosynthesis\
                                                                                                                             Phenylalanine, tyrosine, and tryptophan biosynthesis

  19    Phenylpyruvic acid            165.0420   -13.20        M+H          0.87          0.85^*∗*^     0.97         0.094   Phenylalanine metabolism\
                                                                                                                             Phenylalanine, tyrosine, and tryptophan biosynthesis

  20    Hippuric acid                 178.0494   -3.80         M-H          0.47^*∗*^     0.68^*∗*^     0.96         0.045   Phenylalanine metabolism

  21    Tyrosine                      180.0652   -0.93         M-H          0.85^*∗*^     0.88^*∗*^     0.96         0.045   Phenylalanine metabolism\
                                                                                                                             Aminoacyl-tRNA biosynthesis\
                                                                                                                             Phenylalanine, tyrosine, and tryptophan biosynthesis

  22    3-Indolepropionic acid        190.0737   -7.10         M+H          0.36          0.66          0.54         0.247    

  23    7-Methyluric acid             203.0191   1.05          M+Na-2H      0.89          0.86^*∗*^     0.96         0.024   Caffeine metabolism

  24    Indole-3-lactic acid          204.0640   -2.15         M-H          1.07          1.05^*∗∗*^    0.98^*∗*^    0.07    Tryptophan metabolism

  25    Acetylcarnitine               204.1108   -12.79        M+H          0.93          0.84^*∗*^     0.76^*∗*^    0.017   Fatty acid metabolism (acyl carnitine)

  26    Propionylcarnitine            218.1265   -12.67        M+H          0.67^*∗*^     0.83          0.80         0.033   Fatty acid metabolism (acyl carnitine)

  27    *trans*-Traumatic acid        227.1272   -1.14         M-H          0.87          0.67^*∗*^     0.77         0.053    

  28    Melatonin                     231.1222   8.82          M-H          0.99          0.58^*∗*^     0.59^*∗∗*^   0.063   Tryptophan metabolism

  29    Hexanoylcarnitine             260.1748   -11.40        M+H          0.75^*∗*^     0.83          0.90         0.042   Fatty acid metabolism (acyl carnitine)

  30    Octanoylcarnitine             288.2072   -10.32        M+H          0.68          0.65^*∗*^     0.95         0.033   Fatty acid metabolism (acyl carnitine)

  31    5a-Tetrahydrocorticosterone   315.2278   -4.6          M+H-2H~2~O   0.94          0.84^*∗*^     0.89         0.090    

  32    Decanoylcarnitine             316.2402   -8.55         M+H          0.72          0.71^*∗*^     0.99         0.071   Fatty acid metabolism (acyl carnitine)

  33    Stearoylcarnitine             428.3683   2.29          M+H          1.00          0.85^*∗*^     0.86^*∗*^    0.047   Fatty acid metabolism (acyl carnitine)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SY: Soyangin; TE: Taeeumin; SE: Soeumin. Fold change was calculated by dividing the mean of the peak intensity of each metabolite from each of the two groups. ^*∗*^*p* \< 0.05; ^*∗∗*^*P* \< 0.01; ^*∗∗∗*^*P* \< 0.001.

###### 

Circulating lipid profiles in the three Sasang constitutions.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Identity              m/z        Mass error\   Adduct    MS fragments\        Fold change   *p* value   Pathway               
                                         (mDa)                   (ESI)                                                                
  ----- --------------------- ---------- ------------- --------- -------------------- ------------- ----------- ------------- ------- --------------------------------
  1     FA (20:0)             311.2904   -4.6          M-H       183                  1.18          1.58^*∗*^   1.33          0.116   Lipid metabolism

  2     FA (20:4)             303.2241   -8.3          M-H       183                  1.50^*∗*^     1.53^*∗*^   1.02          0.049   Arachidonic acid metabolism

  3     FA (22:5)             329.2444   -3.7          M-H       183                  1.44^*∗*^     1.47^*∗*^   1.02          0.029   Lipid metabolism

  4     FA (22:6)             327.2340   1.6           M-H       183                  1.88^*∗*^     1.84^*∗*^   0.98          0.005   Lipid metabolism

  5     LPC (16:1)            494.3254   0.72          M+H       476, 184, 104        1.26^*∗*^     1.17        0.93          0.026   Lysolipid metabolism

  6     LPC (18:0)            568.3622   1.1           M+COOH    508, 283, 183, 153   1.25          1.27^*∗*^   1.02          0.064   Lysolipid metabolism

  7     LPE (16:0)            452.2772   -2.00         M-H       255, 214, 196        1.36^*∗*^     1.37^*∗*^   1.01          0.015   Lysolipid metabolism

  8     LPE (18:0)            480.3096   5.2           M-H       283, 214, 196        1.28^*∗*^     1.27        1.00          0.054   Lysolipid metabolism

  9     LPG (16:0)            507.2762   1.1           M+Na      449, 311, 155        0.93^*∗*^     0.94        1.01          0.088   Lysolipid metabolism

  10    LPI (18:0)            599.3170   -2.6          M-H       315, 283, 241        1.23          1.36^*∗*^   1.11          0.044   Lysolipid metabolism

  11    PC (32:0)             734.5695   -0.50         M+H       184                  1.00          1.18^*∗*^   1.18^*∗*^     0.061   Glycerophospholipid metabolism

  12    PC (32:1)             732.5528   1.68          M+H       184                  1.46^*∗*^     1.15        0.79^*∗*^     0.040   Glycerophospholipid metabolism

  13    PC (33:1)             746.5676   -2.38         M+H       184                  1.33^*∗*^     1.10        0.82^*∗*^     0.048   Glycerophospholipid metabolism

  14    PC (34:1)             760.5878   2.22          M+H       184                  1.23^*∗*^     1.05        0.86          0.033   Glycerophospholipid metabolism

  15    PC (36:1)             788.6171   2.97          M+H       184                  1.30^*∗∗*^    1.08        0.83          0.070   Glycerophospholipid metabolism

  16    PC (36:5)             780.5535   -0.81         M+H       184                  1.63^*∗*^     1.19        0.73^*∗*^     0.072   Glycerophospholipid metabolism

  17    PC (36:6)             778.5426   3.94          M+H       184                  1.59^*∗∗*^    1.31        0.82          0.005   Glycerophospholipid metabolism

  18    PC (37:6)             792.5567   2.40          M+H       184                  1.13^*∗*^     1.04        0.93^*∗*^     0.041   Glycerophospholipid metabolism

  19    PC (38:3)             812.6167   -0.18         M+H       184                  1.30^*∗*^     1.08        0.83          0.055   Glycerophospholipid metabolism

  20    PC (38:5)             808.5840   -1.64         M+H       184                  1.35^*∗*^     1.13        0.84          0.084   Glycerophospholipid metabolism

  21    PC (38:6)             806.5732   2.44          M+H       184                  1.22^*∗*^     1.09        0.89          0.063   Glycerophospholipid metabolism

  22    SM (d32:1)            675.5440   -0.13         M+H       184                  1.20^*∗*^     1.18        0.98          0.036   Sphingolipid metabolism

  23    SM (d34:1)            703.5772   2.37          M+H       184                  0.96          1.08        1.13^*∗*^     0.117   Sphingolipid metabolism

  24    SM (d35:1)            717.5886   -2.40         M+H       184                  1.04          1.16^*∗*^   1.12          0.057   Sphingolipid metabolism

  25    SM (d41:1)            801.6847   -0.30         M+H       184                  0.91          1.18        1.29^*∗∗*^    0.052   Sphingolipid metabolism

  26    SM (d42:1)            815.7003   -0.30         M+H       184                  0.90          1.19        1.33^*∗∗*^    0.052   Sphingolipid metabolism

  27    SM (d43:1)            829.7133   -3.05         M+H       184                  0.92          1.19        1.20^*∗∗*^    0.052   Sphingolipid metabolism

  28    1-Deoxysphinganine    286.3099   -0.70         M+H       270                  3.59^*∗*^     4.45^*∗*^   1.24          0.009   Sphingolipid metabolism

  29    Sphinganine (d17:0)   288.2895   -3.53         M+H       282, 264             1.09          1.46        1.34^*∗∗*^    0.197   Sphingolipid metabolism

  30    Sphinganine (d18:1)   300.2907   -2.44         M+H       310                  1.93          1.91^*∗*^   0.99          0.034   Sphingolipid metabolism

  31    Sphinganine (d20:1)   310.3120   -0.25         M+H       268                  1.44^*∗*^     1.24        0.87          0.040   Sphingolipid metabolism

  32    Cholesterol           369.3534   -0.17         M+H       369                  0.98          0.94^*∗*^   0.96          0.061   Primary bile acid biosynthesis

  33    DG (32:0)             591.4954   -3.40         M+Na      551, 313, 257        0.90          1.17        1.30^*∗∗*^    0.012   Glycerolipid metabolism

  34    TG (50:1)             850.7851   -1.82         M+NH~4~   603, 551             1.00          1.30        1.30^*∗∗*^    0.472   Glycerolipid metabolism

  35    TG (52:2)             876.8014   4.19          M+NH~4~   859, 841, 577        1.01          1.20        1.19^*∗∗*^    0.591   Glycerolipid metabolism

  36    TG (54:3)             902.8162   -2.55         M+NH~4~   867, 603, 339        0.95          1.14        1.19^*∗∗∗*^   0.346   Glycerolipid metabolism
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

Fold change was calculated by dividing the mean of the peak intensity of each metabolite from each of the two groups. SY: Soyangin; TE: Taeeumin; SE: Soeumin. ^*∗*^*p* value \< 0.05.

[^1]: Academic Editor: Mohammed S. Ali-Shtayeh
